. During fasting, DNL is very low, owing to increased glucagon and cAMP levels. After eating, blood glucose and insulin level s rise, which stimulates insulin signalling, leading to the activation of specific kinases -including PI3K and downstream kinases such as AKT and atypical protein kinase C (aPKC) -and mTOR complexes (mTORCs), as well as protein phosphatases such as PP1 and PP2, to regulate lipogenesis. If the diet is rich in carbohydrate, blood glucose and insulin levels are elevated to a greater extent, and fatty acid and TAG synthesis is induced to an even higher degree.
Many of the enzymes involved in DNL and in TAG production (BOX 2) are regulated during the fasting-feeding cycle 1 . The activities of these enzymes are maintained at low levels during fasting and are increased after feeding 2 . Such regulation takes place through several mechanisms. Rapid regulation of lipogenic enzymes is achieved by allosteric control and by post-translational modifications such as phosphorylation and dephosphorylation. For example, acetyl-CoA carboxylase (ACC) and 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (PFK2) are activated through dephosphorylation by PP1. PFK2 activation generates fructose-2,6-bisphosphate, which in turn is a potent allosteric activator of PFK1, a crucial regulator y enzyme in glycolysis (BOX 2) .
In the longer term, many of the enzymes that are involved in DNL and in TAG synthesis are primarily regulated at the transcriptional level in a coordinate manner. Transcriptional activation of lipogenic genes after a meal can be achieved through complex mechanisms involving multiple transcription factors, in response to insulin and glucose signalling. Insulin activates specific kinases and phosphatases that modify transcription factors such as upstream-stimulatory factors (USFs), sterol regulatory element-binding protein 1C (SREBP1C), carbohydrate-responsive element-binding protein (ChREBP) and liver X receptors (LXRs) or affect their expression levels (TABLE 1) . Moreover, specific glucose metabolites that increase after a meal can affect the function or localization of some of these transcription factors. The transcription factors are then recruited to the promoter regions of lipogenic genes, where they form complexes with other transcription factors or co-activator s for transcription.
Hyperlipidaemia
Abnormally elevated levels of any or all lipids and/or lipoproteins in the blood.
In this Review, we discuss the main transcription factors and signalling pathways that induce lipogenesis after a meal. Silencing of lipogenic genes during fasting has previously been reviewed 3, 4 . We then discuss the role of chromatin remodelling and circadian rhythms in the regulation of lipogenic gene transcription, as well as the contribution of lipogenesis to hepatosteatosis and insulin resistance.
USFs for lipogenic gene activation by insulin USF1 and USF2 are basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factors and form homo-or heterodimers to bind to an E-box, at target promoters for transcriptional activation 5 . The requirement for USFs in lipogenesis has been demonstrated in vivo in Usf1-or Usf2-knockout mice that show substantially impaired lipogenic gene activation following highcarbohydrate feeding 6 . However, USF ablation did not affect insulin resistance, probably because USFs could affect lipo genesis but not glucose metabolism [6] [7] [8] . Mice overexpressing USFs in liver cells may also be of use in understanding the role of USFs in hepatosteatosis and insulin resistance. Regardless, quantitative trait-mappin g studies have identified Usf1 as a candidate gene for familia l combined hyperlipidaemia 9 . USFs were found to bind to the proximal promoter region of the gene encoding fatty acid synthase (FAS; also known as FASN), which is a key enzyme in lipogenesis 10 . USFs have been shown to be required for Fas promoter activation by insulin, by binding to the −65 E-box 11 (FIG. 1) . In this regard, USFs were originally shown to bind to the L-type pyruvate kinase (Lpk; also known as Pklr) promoter when both glucose and insulin levels are elevated 12, 13 . Consistent with the role of USF binding to the E-box, mutations in the -65 E-box abolish the response of the Fas promoter to insulin in cultured cells. Overexpression of dominant-negative USF1 or USF2 mutants that lack the DNA-binding domain impairs insulin stimulation of Fas promoter activity 5 . The Fas promoter has also been examined in transgenic mice with various 5ʹ deletions of the Fas promoter region fused to the chloramphenicol acetyltransferase (cat) reporter gene, as well as mutation of the -65 E-box 14 . CAT reporter activity measurements and chromatin immunoprecipitation (ChIP) of livers from these transgenic mice showed that USF1 and USF2 are bound to the E-boxes at -332 and -65 of the Fas promoter 15 . Deletion or mutation of the -65 E-box abolishes feeding-or insulin-dependent activation of the Fas promoter, providing in vivo evidence of the requirement for the -65 E-box in the response to feeding and insulin treatment. Additionally, presence of the -332 E-box increases promoter activation further, showing the importance of this second -332 E-box in Fas promoter activation 15 .
Phosphorylation and acetylation of USF1. USF levels do not change during the fasting-feeding cycle, and USFs are bound to the E-box at the promoter regions of Fas and of genes encoding other lipogenic enzymes, such as mitochondrial glycerol-3-phosphate acyltransferase (mGPAT), under both conditions [16] [17] [18] [19] [20] . This suggests that post-translational modification(s) of USFs may occur during fasting-feeding. Indeed, mass spectrometry analysis of liver nuclear extracts from fasted and fed mice revealed feeding-specific S262 phosphorylation and K237 acetylation of USF1 (REFS 21, 22) . S262A and S262D phosphorylation mutants, as well as K237R and K237A acetylation mutants of USF1, were used to test the importance of these post-translational modifications. Activation of the Fas promoter was higher with S262D-and K237A-mutant forms of USF1, which mimic hyperphosphorylation and hyperacetylation, respectively. Conversely, S262A and K237R mutants, which mimic dephosphorylation and deacetylation, respectively, could not effectively activate the Fas promoter. These studies clearly demonstrated the importance of S262 phosphorylation and K237 acetylation for USF function in transcriptional activation following feeding or insulin treatment (FIG. 2) .
In defining signalling pathways and mechanisms that lead to post-translational modification of USF1, various USF1-interacting proteins that are specific to fasting or to feeding have been identified by tandem affinity purification followed by mass spectrometry analysis. The enzymes identified include DNA-dependent protein kinase (DNA-PK), which is a kinase known to be involved in DNA damage repair, and its regulatory subunits Ku70 and Ku80; PP1, which can dephosphorylate Box 1 | Insulin and glucagon regulate blood glucose levels and lipid metabolism Glucose and lipid metabolism are regulated together to balance energy use and storage, in order to maintain blood glucose concentrations within a narrow range. Glucagon and insulin, which are secreted from pancreatic islets, have opposing roles in the regulation of glucose and lipid metabolism. Following fasting, low glucose levels stimulate the secretion (from islet α-cells) of glucagon, which functions mainly in the liver to increase hepatic glucose production by increasing glycogenolysis (the enzymatic breakdown of glycogen) and gluconeogenesis (the synthesis of glucose, mainly from lactate and amino acids), involving the protein kinase A (PKA)-cAMP signalling pathway. By contrast, high glucose levels (for example, after the ingestion of carbohydrates) trigger the secretion (from pancreatic β-cells) of insulin, which stimulates glucose uptake and utilization and promotes glycogen and fatty acid synthesis in the liver. Fatty acids generated from de novo lipogenesis (DNL), along with those taken up from circulation, are then used for sequential esterification of the glycerol backbone to produce triacylglycerols (TAGs) in the liver. TAGs are secreted into circulation as very low-density lipoproteins (VLDLs). VLDL secretion is followed by the lipoprotein lipase (LPL)-mediated mobilization of TAGs to fatty acids, which are taken up by adipose tissue for long-term storage after re-esterification. DNL and fat synthesis are executed by a series of enzymes (see BOX 2) that are regulated to enable metabolic homeostasis to adapt to changing nutritional and hormonal conditions.
Poly (ADP-ribose) polymerase 1 (PARP1). A nuclear protein, the main role of which is to detect and signal single-strand breaks (SSBs) in DNA to the enzymatic machinery involved in SSB repair. PARP1 activation is an immediate cellular response to metabolic, chemical or radiation-induced DNA SSB damage.
and activate DNA-PK; poly(ADP-ribose) polymerase 1 (PARP1); topoisomerase IIβ; and p300/CBP-associated factor (PCAF; also known as KAT2B) 21, 22 . It has been shown that following feeding or insulin treatment, PP1 translocates to the nucleus to dephosphorylate and activate DNA-PK (FIG. 1) . Decreased lipogenic gene expression with impaired hepatic lipogenesis and lower TAG levels in DNA-PK-deficient mice with severe combined immunodeficiency (SCID) demonstrated the crucial role of DNA-PK in lipogenic gene activation 21, 22 . DNA-PK can phosphorylate USF1 at S262 in vitro, as well as in vivo following feeding or insulin treatment. Moreover, S262 phosphorylation promotes the recruitment of and interaction with PCAF, which in turn acetylates USF1 at K237 (REFS 21,22) (FIG. 1) .
By contrast, during fasting, USF1 preferentially interacts with histone deacetylase 9 (HDAC9), which can deacetylate USF1, preventing the recruitment of these factors for transcriptional activation 21, 22 (FIG. 2) . Consistent with a role for post-translational modifications of USF1 in transcriptional activation following feeding, USF1 S262 phosphorylation and K237 acetylation on the Fas promoter and other lipogenic promoters were detected with ChIP only under fed conditions, whereas dephosphorylated and deacetylated USF1 was found on these promoters under fasted conditions. Post-translational modification of USF1 has also been implicated in the suppression of gluconeogenesis. It was reported that USF1 is activated by AMP-activated protein kinase (AMPK) in a DNA-PK-dependent manner, stimulating hepatic transcription of the tyrosine phosphatase inhibitor SHP (also known as NR0B2). This resulted in suppression of the transcription of phosphoenolpyruvate carboxykinase and the glucose-6-phosphatase catalytic subunit (G6PC), thereby reducing glucose production 23 . These studies suggest that USFs that are phosphorylated by DNA-PK may participate in coordinating changes in lipogenesis and gluconeogenesis during the fasting-feeding cycle.
Interestingly, in addition to DNA-PK and PCAF, other DNA damage-repair components, including PARP1 and topoisomerase IIβ, were found in the USF1 complex at the Fas promoter 21, 22 , and transient DNA breaks were detected during feeding-induced Fas gene activation 21, 22 . PARP1 and topoisomerases have previously been reported to be involved in ligand-dependent transcriptional activation by nuclear hormone receptors [24] [25] [26] [27] . The authors of these works proposed that transient DNA breaks may release torsion stress generated by RNA poly merase II (Pol II)-dependent transcription. A similar mechanism may occur during transcription activated by USF1.
Lipogenic gene activation by SREBP1C
SREBPs are bHLH-LZ transcription factors that bind as dimers to sterol regulatory elements (SREs) of target genes involved in lipid metabolism. There are three SREBP isoforms -SREBP1A, SREBP1C, and SREBP2 -of which SREBP1C is primarily responsible for the expression of lipogenic genes, although there is some functional overlap between different SREBPs. A crucial role for SREBP1C in the transcriptional activation of lipogenic genes has been shown in vivo by overexpression of SREBP1C in the livers of mice, which leads to increased hepatic lipid accumulation and insulin resistance 28, 29 . Accordingly, insulin-resistan t obese mice with hepatosteatosis show constitutively elevated SREBP1C expression 30, 31 . Conversely, Srebp1c-knockout mice showed defects in the induction of lipogenic enzymes by feeding 28 . However, induction of lipogenic genes was diminished by approximately 50%, but was not completely eliminated, by SREBP1C ablation 32 . Thus, SREBP1C activity alone cannot account for full stimulation of liver fatty acid and TAG synthesis in response to a high-carbohydrate diet. Although it is possible that other SREBP isoforms might compensate for SREBP1C, the partial effect of SREBP1C ablation on hepatic lipogenesis is more likely to reflect Box 2 | Metabolic pathways for fatty acid and TAG synthesis Glucose taken up by the cell is converted to pyruvate through glycolysis. Pyruvate is further converted into acetyl-CoA and enters the tricarboxylic acid (TCA) cycle (which is also known as the Krebs cycle for energy production). Excess acetyl-CoA converted to citrate can exit the mitochondria and becomes the substrate for lipogenic enzymes. Enzymes involved in fatty acid and triacylglycerol (TAG) synthesis include:
• Glycolytic enzymes, such as glucokinase (GK), phosphofructokinase 1 (PKF1) and PKF2, and liver pyruvate kinase (LPK), which provide the carbon source for fatty acid and TAG synthesis • Enzymes for the fatty acid synthetic pathway, such as ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), elongase of long chain fatty acids family 6 (ELOV6) and stearoyl-CoA desaturase (SCD) • Enzymes for the production of NADPH used in fatty acid synthesis, including the oxidative branch of the pentose-phosphate pathway, such as glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (PGD), as well as malic enzyme (ME) • Enzymes involved in esterification for TAG production, such as mitochondrial g lycerol-3-phosphate acyltransferase (mGPAT), 1-acylglycerol-3-phosphate acyltransferase (AGPAT), phosphatidate phosphatase (PAP) and diacylglycerol acyltransferase (DGAT) Nature Reviews | Molecular Cell Biology A transcriptional coactivator that has in vitro and in vivo binding activity with CREB-binding protein (CBP) and p300, and competes with E1A for binding sites in p300 and CBP. PCAF has histone acetyl transferase activity with core histones and nucleosome core particles, indicating that it plays a direct part in transcriptional regulation.
the contribution of other transcription factor(s), such as USFs, ChREBP and LXRs, which are required for or enhance lipogenic gene induction.
USFs recruit SREBP1C to lipogenic promoters. Although
SREBPs are known to function by binding to SREs, because of an atypical tyrosine residue that replaces a conserved arginine that is present in their basic regions, SREBPs can also bind to E-boxes, at least in vitro 33, 34 . It has been reported that SREBPs bind to the -65 E-box of the Fas promoter for activation 35 , whereas we and other s have reported SREBPs binding to the nearby -150 SRE 36, 37 . However, ChIP using transgenic mice with a Fas promoter-cat reporter that had a mutation at the -150 SRE or -65 E-box firmly established in vivo that SREBPs bind to the -150 SRE, but not the -65 E-box, to activate the Fas promoter [36] [37] [38] . Importantly, although binding of SRBEP1C to the -150 SRE is crucial for the feeding and insulin response, SREBP1C could not bind to the SRE when the binding site for USFs in the -65 E-box was mutated in vivo. These observations suggest a potential interaction between the two transcription factors and highlight the role of USFs in the transcriptional activation of lipogenic genes 36 (FIG. 1) . In addition, SREBPs have been shown to function together with other transcription factors, such as SP1 and nuclear factor Y (NF-Y), for transcriptional activation [39] [40] [41] [42] . For example, although the physical interaction has not been examined, SREBP1 and SP1 have been reported to cooperate at adjacent sites to activate the Fas and Acc promoters 43, 44 . The requirement of USFs for SREBP1C function was also revealed by USFknockout mice that showed severely delayed Fas induction during feeding, even when the level of the mature form of the SREBP remained unchanged 6 . In fact, interaction between USFs and SREBP1C have been shown to occur both in vitro and in vivo 37 . The bHLH domain of USFs interacts directly with the bHLH domain of the amino-terminal region of SREBP1C. Moreover, co-transfectio n of USF1 and SREBP1C indicated that these two transcription factors function synergistically to activate the Fas promoter. Furthermore, functional domain mapping using Usf1-and Srebp1c-deletion constructs indicated that the activation domains of both protein s are required for this functional synergy.
Moreover, co-immunoprecipitation studies using USF1 mutants containing S262D and S262A showed that S262 phosphorylation increases its interaction with SREBP1C 21 . This indicates that post-translational modifications of USF1 are crucial for the recruitment of SREBP1C to bind to the nearby SRE for the synergistic activation of lipogenic genes by USFs and SREBP1C during feeding or insulin treatment 21 . A similar synergistic effect of USF1 and SREBP1C was observed for activation of the mGpat promoter 45 . Numerous lipogenic genes, including Srebp1c, Acc, ATP citrate lyase (Acly) and mGpat, contain an E-box and an SRE at their promoter regions, suggesting a common mechanism for the recruitment of SREBP1C by USFs in the induction of lipogenic genes.
Regulation of SREBP1C expression and cleavage. As mentioned above, during the fasting-feeding transition, SREBP1C expression levels are similar to those of other lipogenic enzymes and are probably controlled by a common transcriptional regulatory mechanism. It can be predicted that, by directly interacting with SREBP1C, USF1 recruits SREBP1C to bind to an SRE at the Srebp1c promoter region for transcriptional activation 21 . In agreement with this prediction, expression of SREBP1C is induced by SREBP1C itself, and USF binding to the Srebp1c promoter region has been detected using ChIP 36, 46 . USF1 phosphorylation by DNA-PK enhances binding of SREBP1C to the promoter region of its own gene, as observed with other lipogenic genes. In addition, as described below in more detail, LXRα can bind to and activate lipogenic promoters, including Srebp1c 32, 47 , to induce lipogenesis.
Unlike most transcription factors, SREBP1C (as is the case for all SREBPs) resides at the endoplasmic reticulum (ER) membrane as a larger precursor complex with SREBP cleavage-activating protein (SCAP) • P-S117, P-S63 and P-T426 by MAPK • AC-K289 and K309 by p300
• P-S31 and P-S314 by PKA 
ATP-binding cassette (ABC) transporters
Transmembrane proteins that utilize the energy from ATP binding and hydrolysis to carry out certain biological processes, including translocation of various substrates across membranes.
and insulin-induced gene (INSIG) proteins. After proteolytic cleavage, the mature N-terminal SREBP1C trans locates into the nucleus, where it binds to SREs to activate transcription (FIG. 1) . Insulin activates SREBP1C cleavag e through two mechanisms that involve AKT and mTORC1. Although specific phosphorylation site(s) are not known, AKT has been shown to directly phosphorylate SREBP1C. Phosphorylation increases the affinity of the SCAP-SREBP1C complex for the SAR1-SEC23-SEC24 complex found on COPII-coated vesicles, which facilitates the transport of SREBP1C to the Golgi, where SREBP1C can undergo cleavage 48 . Processing of SREBP1C following insulin stimulation has also been reported to depend on mTORC1 and its downstream target kinase, p70 ribosomal S6 kinase (p70S6K) [49] [50] [51] . In addition, it has been reported that mTORC1-independen t AKT activation caused a decrease in Insig2a mRNA levels and thus in the size of the Insig2a pool at the ER membrane, releasing SCAP-SREBP1C and allowin g it to be transported into the Golgi 52, 53 . SREBPs have also been reported to be phosphorylated by MAPK family kinases p38, ERK and JNK at various sites 54 . Mice overexpressing SREBP1A containing S63, S117 and T426 phosphorylation-site mutations were protected from development of hepatosteatosis 55 . Since these phosphorylation sites are found in the mature forms of SREBPs and are conserved in SREBP1C, MAPK may play a part in regulating SREBP1C function in lipogenic gene activation, by affecting either DNA binding or transactivation. In addition, SREBP1 was reported to be phosphorylated by protein kinase A (PKA) at S314, resulting in attenuation of SREBP1 binding to SREs at the lipogenic promoter regions 56 . The N-terminal region of SREBP1C was also reported to be phosphorylated by glycogen synthase kinase 3 (GSK3), which is inactivated upon its phosphorylation by AKT to negatively regulate SREBP1C 57 . SREBP1C may also undergo acetylation and deacetylation. SREBP1C was reported to be acetylated at K289 and K309 by p300-CREB-binding protein (CBP) under conditions of high glucose and insulin (FIG. 1) and can be deacetylated by sirtuin 1 (SIRT1). Deacetylation of SREBP1C by SIRT1 inhibited its binding to its target lipogenic promoters 31 . Interestingly, deacetylation of SREBP1C by SIRT1 has also been reported to promote the ubiquitylation and proteasomal degradation of SREBP1C, indicating dual effects of SREBP1C acetylation 31, 58 . In addition, during nutritional deprivation, PKA-mediated phosphorylation of SREBP1C increases the interaction of SREBP1C with protein inhibitor of activated STAT protein y (PIASy; also known as PIAS4), which is a small ubiquitin-related modifier (SUMO) E3 ligase, thus augmenting sumoylation of SREBP1C at K98 and leading to SREBP1C degradation 59 . These studies illustrate how different posttranslationa l modifications of SREBP1C operate together in regulating lipogenic gene transcription.
LXRs activate lipogenic genes
LXRs belong to the nuclear hormone receptor superfamily of sterol-regulated transcription factors that are activated by the binding of physiological ligands, such as oxysterols 60, 61 , and by certain intermediates in the cholesterol biosynthetic pathway, such as desmosterol. LXR target genes include genes encoding ATP-binding cassett e (ABC) transporters such as ABCA1, ABCG1, ABCG5 and ABCG8 (REF. 62 ), and apolipoprotein E 63 , which have centra l roles in liver cholesterol metabolism. Two isoforms of LXR, LXRα and LXRβ, bind to LXR response elements (LXREs) at target promoter regions, with their obligate partner, 9-cis retinoic acid receptor (RXR) (FIG. 1) . Of the two LXR isoforms, LXRα is more abundantly found in lipogenic tissues such as liver. Mice ablated of both LXRα and LXRβ showed defective hepatic lipid metabolism, decreasing lipogenesis by 80%, and were resistant to obesity, demonstrating the role of LXRs in hepatic lipogenesis 47, 64, 65 . Although they remained obese, LXRα-and LXRβ-deficiency in leptin-deficient (ob/ob) mice also reduced hepatosteatosis. and mTORC2, and DNA-dependent protein kinase (DNA-PK), as well as protein phosphatases such as PP1 and PP2. These kinases and phosphatases modify transcription factors by phosphorylation or dephosphorylation, respectively. Activated transcription factors, including upstream stimulatory factor 1 (USF1), sterol regulatory element-binding protein 1C (SREBP1C), carbohydrate-responsive element-binding protein (ChREBP) and liver X receptors (LXRs), bind to lipogenic gene promoter regions at the E-box (5ʹ-CATGTG-3ʹ), sterol regulatory element (SRE; 5ʹ-TCACNCCAC-3ʹ), carbohydrate response element (ChoRE; 5ʹ-CAYGNGN 5 CNCRTG-3ʹ) and LXR response element (LXRE; 5ʹ-AGGTCAN 4 AGGTCA-3ʹ), respectively, for transcriptional activation. USF1 also recruits the lipoBAF complex, leading to chromatin remodelling for transcription. BAF, BRG1/ BRM-associated factor; F-2,6-P 2 , fructose-2,6-bisphosphate; G-6-P, glucose-6-phosphate; GLUT, glucose transporter; IGF, insulin-like growth factor; MLX, Max-like protein X; NCOA6, nuclear receptor coactivator 6; PCAF, p300/ CBP-associated factor; RXR, retinoic acid receptor; TSC, tuberous sclerosis; X-5-P, xylulose 5-phosphate.
It has been shown that LXRα can increase lipogenic gene transcription by binding to and activating SREBP1C 47, 66, 67 . ChREBP (see below) may also be a target of LXRs, as two LXREs were reported at Chrebp promoter regions, and LXR agonist treatment increased ChREBP expression 68, 69 . However, ChREBP expression was reported to be unaltered in LXRα-or LXRβ-ablated mice, contradicting ChREBP as a target of LXRs 70 . Regardless, LXREs are also found in the promoter regions of several lipogenic genes, such as those encoding FAS, ACC and stearoyl-CoA desaturase 1 (SCD1), as well as LXRα itself. In fact, activation of the Fas promoter, which contains an LXRE at the -700 bp region, has been reported 71 . Therefore, LXRs may activate lipogenic gene transcription directly, as well as indirectly through induction of SREBP1C and ChREBP 71, 72 . It is generally believed that LXRs function in insulin-mediated lipogenesis 67 , but physiologically relevant ligand(s) of LXRs for lipogenic activation have not been well established. It has been reported that glucose and glucose-6-phosphate can bind directly to LXRs 69 to stimulate transcription of their target genes. It has also been reported that LXRs interact with O-linked ß-N-acetylglucosamine (O-GlcNAc) transferase and are modified by O-GlcNAc for glucose sensing to induce LXR target genes [73] [74] [75] . Under hyperglycaemic and hypoinsulinaemic conditions, LXRs maintain the ability to upregulate the expression of glycolytic and lipogenic enzymes, including glucokinase, SREBP1C, ChREBPα and ChREBPβ 71 . However, others have reported that LXRs are not required for induction of ChREBP-or glucose-regulated genes, which suggests that either glucose and its metabolites are not physiological ligands for LXRs, or the post-translational modification of LXRs does not represent a glucose-sensing mechanism. Regardless, following agonist binding, the conformation of the LXR-RXR complex may change to release co-repressors such as silencing mediator of retinoic acid and thyroid hormone receptor (SMRT; also known as NCoR2) and NCoR1, and to bind to nuclear receptor coactivators such as E1A-associated protein p300 (EP300) and activating signal co-integrator 2 (ASC2; also known as NCOA6) 76, 77 (FIG. 1) .
During fasting, LXRα can be phosphorylated by PKA at S195 and S196 and at S290 and S291, which prevents dimerization with RXR and binding to LXRE, and recruits the co-repressor NcoR1 rather than the coactivator SCR1 (REF. 78 ). Although the specific site(s) are not known, AMPK has also been reported to phosphorylate LXRα at a threonine residues (or residues), resulting in the inhibition and attenuation of TAG synthesis, directly opposing its phosphorylation at serine residues by S6K1, which is activated through mTORC1 (described in more detail below) 79 .
ChREBP mediates lipogenic gene activation
ChREBP was purified and identified by DNA affinity purification using the Lpk promoter sequence that responds to glucose, in which other E-box binding transcription factors, such as USFs (which are also known as major late transcription factors (MLTFs)) were previously implicated. Nevertheless, ChREBP has been shown to be the bona fide transcription factor that is primarily responsive to glucose. ChREBP has a bHLH-LZ domain and forms a heterodimeric complex with another bHLH-LZ protein, Max-like protein X (MLX), to bind to a carbohydrate response element (ChoRE), which is composed of two E-boxes separated by five base pairs, at the promoter regions of target genes [80] [81] [82] (FIG. 1) .
Well-accepted targets of ChREBP include not only genes encoding enzymes in glucose metabolism such as LPK, G6PC, glucose transporter type 4 (GLUT4; also known as SLC2A4), glycerol-3-phosphate dehydrogenase (GPDH) and glucokinase regulatory protein (GKRP) 80, 83 , but also those encoding lipogenic enzymes such as ACLY, FAS, ACC and SCD1 (REFS 84, 85) . Recently, it has been reported that a full-length isoform of ChREBP (also known as ChREBPα), named ChREBPβ, which is derived from an alternative promoter and is shorter than the conventional isoform ChREBPα, has higher transcriptional activity 86, 87 . Because ChREBP regulates both glucose and lipid metabolism, ChREBP causes USF1 and USF2 form homo-or heterodimers that bind to the E-box at lipogenic promoter regions. Although USF1 and USF2 bind under both fasted and fed conditions, USF1 is phosphorylated and acetylated in the fed, but not the fasted, condition. Owing to differential modifications of USF1, interacting partners are different under fasted and fed conditions. In fasting, USFs interact with histone deacetylase 9 (HDAC9), which can deacetylate USF1 to prevent the recruitment of DNA-dependent protein kinase (DNA-PK) and p300/CBP-associated factor (PCAF), and lipogenic genes are not activated. Upon feeding, USFs are phosphorylated by DNA-PK, which is dephosphorylated and activated by protein phosphatase 1 (PP1), and subsequently acetylated by PCAF to activate transcription. Phosphorylated and acetylated USF1 can interact with BRG1-associated factor BAF60C, which is first phosphorylated by atypical PKC (aPKC) and translocates from the cytosol to the nucleus. BAF60C functions as a bridge for the recruitment of the lipoBAF complex containing BRG1 that has the ATPase activity, BAF155, and BAF250 for chromatin remodelling for lipogenic gene transcription. Ac, acetyl; SRE, sterol regulatory element; SREBP1C, sterol regulatory element-binding protein 1C.
complex metabolic changes in loss-and gain-of-function studies 88 . ChREBP-ablated mice show not only reduced glycolysis but also an approximately 60% reduction in lipogenesis, and these mice exhibited insulin resistance 85 . However, liver-specific ChREBP deletion by adenoviral short hairpin RNAs (shRNAs) improves hepatosteatosis but also improves insulin resistance in ob/ob mice 89 . Conversely, adenoviral overexpression of ChREBP in liver increases hepatic TAG levels but blunts high-fat diet (HFD)-induced insulin resistance 90 . Overall, these studies demonstrate the involvement of ChREBP in lipogenic gene transcription but might dissociate hepatosteatosis from insulin resistance. Consistent with this observation, hepatic ChREBP expression has been reported to increase in patients with non-alcoholic steatohepatitis when steatosis was greater than 50%, but to decrease when steatosis was accompanied by severe insulin resistance 90 . ChREBP undergoes post-translational modification. During fasting, ChREBP can be phosphorylated by PKA at S196 and T666, causing prevention of nuclear entry and decreasing its DNA binding, respectively 91, 92 . In addition, phosphorylation of ChREBP at S586 by AMPK also decreases its DNA-binding activity 93 . ChREBP phosphorylated by PKA at S140 and S196 binds to 14-3-3 proteins with higher affinity, retaining ChREBP in the cytosolic compartment [94] [95] [96] . Under high-glucose conditions, ChREBP is dephosphorylated to become an active form and is translocated into the nucleus to increase binding of ChREBP to its response element 92 . ChREBP may be regulated by xylulose-5-phosphate, which is an intermediate of the pentose-phosphate shunt that is activated under high-glucose conditions and that has been reported to specifically activate PP2A for ChREBP dephosphorylation 91 (FIG. 1) . It has also been reported, although the underlying mechanism is not clear, that other phosphometabolites that are generated during glucose metabolism, such as glucose-6-phosphate and fructose-2,6-bisphosphate, promote nuclear translocation of ChREBP 95, 97 . Furthermore, acetylation of ChREBP at K672 by p300 has also been shown to increase its recruitment to the promoter regions of target genes 98 . Incidentally, intramolecular interaction has been proposed to be a mode of controlling ChREBP activity. ChREBP contains both a low-glucose inhibitory domain (LID) and a glucose response-activation conserved element (GRACE). LID inhibits the ChREBP transactivation activity conferred by GRACE, and this inhibition is lifted under high-glucose conditions 94, 99, 100 . Accordingly, ChREBP would be modified in a manner that relieves the repressive intramolecular interaction under high-glucose conditions.
In addition, similar to SREBP1C, transcription of ChREBP itself is induced by glucose and exhibits a feed-forward autoregulation by binding of ChREBP to its own ChoRE 83 . LXRs have been shown to directly bind to the promoter region to transcriptionally activate ChREBP 68, 69 , although others have reported that LXRs are not required for induction of the gene encoding ChREBP or other glucose-regulated genes, as stated above.
Protein stability may also be a mode of regulation of ChREBP levels. ChREBP has been shown to undergo O-GlcNAcylation under high-glucose conditions, resulting in its stabilization and potentially affecting its phosphorylation 101, 102 . Treating cells with PUGNAc, which is an inhibitor of O-GlcNAcase, or overexpression of O-GlcNAc transferase, increased ChREBP function and lipogenic gene expression under high-glucose conditions. Conversely, treating cells with 6-diazo-5-oxo-l-norleucine, which is an inhibitor of glutamine fructose amidotransferase that decreases O-GlcNAc modification, or overexpression of O-GlcNAcase, blocked lipogenic gene expression in vitro and in vivo 101, 102 .
Chromatin remodelling for lipogenesis Dynamic chromatin structure has an essential role in the control of gene transcription. Although low endonuclease accessibility of the Fas and mGpat promoter regions is observed during serum starvation, the endonuclease accessibility is remarkably increased upon insulin treatment. These observations demonstrate altered chromatin structure of lipogenic promoter regions during the fasting-feeding cycle 103 . Two highly conserved mechanisms underlie the alteration of chromosome structure: the post-translational modification of histones and ATP-dependent chromosome remodelling. Modifications of histones include acetylation, methylation and phosphorylation, which primarily occur at N-terminal tails. Many of these enzymes, such as p300/ CBP and PCAF, which are involved in lipogenic gene transcription, were originally described as proteins for general transcription, and p300/CBP is found to be associated with the Pol II holoenzyme. In this regard, as is observed for most transcriptionally active genes, acetylation of histone H3 at K14 and phosphorylation of H3 at S10 were found at the Fas promoter region, along with Pol II, in response to feeding and insulin 103 .
As the methylation status of histones has been shown to be important for transcription, especially that of H3 tail regions, efforts have been made to characterize the effects of methylation and demethylation on transcriptional regulation. Upon feeding or insulin treatment, activation marks such as H3K4me2, H3K4me2 and H3K79me3 are predicted at lipogenic promoter regions. Conversely, the repressive mark H4K20me3 may be detected in fasting. In this regard, lysinespecific histone demethylase LSD1 functions on H3K4 and H3K9 for repression and activation, respectively. LSD1 has recently been reported to be required for activation of the Fas promoter by SREBP1. Transfection of an LSD1 mutant lacking a demethylase domain or treating cells with LSD1 inhibitor trans-2-phenylcyclopropylamine caused a decrease in lipogenic gene expression 104 . Histone modifications at the lipogenic genes in the liver during feeding or insulin treatment need furthe r investigation.
In addition to histone post-translational modifications, the BAF (BRG1/BRM-associated factor) complex, which carries out ATP-dependent chromatin remodelling, has been shown to function in lipogenic transcription. The BAF complex belongs to the mammalian SWI/SNF complex and is composed of transcription activator BRG1 (also known as BAF190) or BRM (also known as SNF2L2), which has the ATPase activity, and other BAF subunits that act as modulators, such as BAF155, BAF170 and BAF250, as well as BAF57 and BAF60, which interact with transcription factors. Recent studies have revealed that, by direct binding, USF1 recruits BAF60C, one of the three isoforms of BAF60, which in turn recruits other BAF subunits, such as BRG1, BAF155 and BAF250, to form the lipoBAF complex for chromatin remodelling that is required for activation of the lipogenic programme upon feeding or insulin treatment 103 (FIG. 2) . Consistently, knockdown of Baf60c resulted in a decrease in hepatic lipogenesis, whereas overexpression of BAF60C caused lipogenic induction in vivo 103 . In addition, reduced endonuclease accessibility of chromatin was detected upon knockdown of Baf60c at the lipogenic gene promoter region.
Upon feeding or insulin treatment, BAF60C was found to be phosphorylated at S247 by aPKC, PKCλ and PKCζ. S247 phosphorylation was abolished by short interfering RNA (siRNA)-mediated knockdown of aPKC or by overexpression of dominant-negative aPKC, indicating that aPKC phosphorylates S247 of BAF60C. Phosphorylated BAF60C then translocates from the cytosol to the nucleus. Phosphorylated BAF60C directly interacts with phosphorylated and acetylated USF1 to allow recruitment of the lipoBAF complex to lipogenic promoter regions, for remodelling of chromatin in a manner conducive to transcription. Furthermore, USF1 phosphorylation by DNA-PK and subsequent acetylation by PCAF, and BAF60C phosphorylation by aPKC, are both required for their direct interaction that results in chromatin remodelling of the lipogenic genes. In fact, in addition to AKT, insulin-mediated activation of aPKC, PKCλ and PKCζ has been shown to increase SREBP1C expression and lipogenesis 105 . Liverspecific knockout of the gene encoding PKCλ leads to a marked decrease in SREBP1C expression 106 . BAF60C phosphorylation may be the underlying mechanism for this observation. Interestingly, it has been reported that during fasting, BAF60A, by interacting with peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α), recruits the SWI/SNF complex to various fatty acid oxidativ e genes, including acetyl-CoA acyltransferase B (Acaa1b) and acyl-CoA oxidase 1 (Acox1) 107 . This suggests an isoform-specific function of BAF60s for chromatin remodelling during different metabolic states. It would be interesting to examine whether BAF60A is post-translationally modified during fasting to increase its interaction with PGC1α.
Role of mTOR in lipogenic gene activation During the energy-abundant fed state, lipogenesis may also be activated by the mTOR pathway, which is known to control cell growth and metabolism in response to nutrients, growth factors or energy status 108 . mTOR exists as distinct complexes, TORC1 and TORC2, which function independently. mTORC1 has been shown to increase SREBP1C expression upon AKT-mediated phosphorylation of the tuberous sclerosis 1 (TSC1)-TSC2 protein complex, which inhibits mTORC1 activity (FIG. 1) . Although mTORC1 has been shown to be essential 109 for lipogenesis and to increase SREBP1C expression, ablation of TSC1 (which is a negative regulator of mTORC1), did not increase SREBP1C expression 51, 53 . The AKT-mediated suppression of Insig2a may explain this discrepancy. Upon insulin signalling, mTORC2 has also been shown to induce SREBP1C expression through an activating S473 phosphorylation of AKT 110 (FIG. 1) . Consistent with this observation, liver-specific ablation of an mTORC2 component, RICTOR, impaired hepatic lipogenesis. However, constitutively active AKT2 could not fully restore lipogenesis in mTORC2-deficient hepatocytes, suggesting the involvement of an AKTindependent mechanism 111 . Moreover, whether the mTOR pathway activates lipogenic genes only indirectly through induction of SREBP1C expression as reported, or also by directly affecting transcriptio n factor function, has not been examined.
Lipogenic gene regulation by circadian rhythms
In addition to being regulated during fasting-feeding, lipogenesis fluctuates during the circadian day-night cycle 112
. Food intake, in turn, can affect circadian rhythm [113] [114] [115] . Circadian-regulated lipogenesis in the liver has been reported to function through reverse-ERB-α (REV-ERBα; also known as NR1D1) and REV-ERBβ (also known as NR1D2), and through retinoic acid receptor-related orphan receptors (RORα, RORβ and RORγ). These can bind as a monomer to their response element (RORE) 5ʹ-AGGTCA-3ʹ 'half site' with a 5ʹ AT-rich extension 116 . By recruitment of specific repressors or co-activators, REV-ERB and ROR receptors can repress and activate gene transcription, respectively (FIG. 3) . In rodents, during the light period when they are inactive, as REV-ERBα and REV-ERBβ
Box 3 | Regulation of circadian rhythm
The core mammalian clock is composed of a heterodimer of the transcription factors circadian locomotor output cycles protein kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1), which activate their own transcription and that of genes encoding period circadian clock (PER) and cryptochrome (CRY), via E-box sequences within their promoters. PER and CRY proteins form dimers that disrupt the CLOCK-BMAL1 transcription complex and therefore inhibit CLOCK and BMAL1 transcription, thus suppressing their activity. The peak expression of the CLOCK-BMAL1 complex is 12 hours out of phase with peak PER and CRY expression, to form the 24-hour pacemaker. Expression of both retinoic acid receptor-related orphan receptors (RORs) and reverse-ERB (REV-ERB) receptors is regulated by the CLOCK-BMAL1 and PER-CRY loops and undergoes circadian oscillations. Conversely, ROR and REV-ERBα and REV-ERBβ feed back to activate or suppress transcription of CLOCK and BMAL1, respectively expression levels rise, they recruit HDAC3, preventing lipogenic gene activation 117 . Conversely, during the dark time of the active period in rodents, REV-ERBα and REV-ERBβ levels are low and lipogenic genes are activated. Two groups of researchers reported that deletion of the gene encoding REV-ERBα in mice alters glucose and lipid metabolism, leading to elevation of circulating TAG levels and exacerbated hepatosteatosis [118] [119] [120] [121] . Furthermore, it has been shown that REV-ERBs recruit HDAC3 through NCoRs 122 . ChIP sequencing has revealed that HDAC3 is enriched in >100 lipid biosynthetic genes, including Fas, Scd1 and Acly, during the light time, but less during the dark period, which inversely correlates with histone acetylation and Pol II recruitment 121 . Histone deacetylation by HDAC3 alone, however, was insufficient for lipogenic gene suppression but required interaction with NCoRs. Thus, liver-specific ablation of NCoRs in mice causes metabolic and transcriptional alterations similar to those caused by hepatic ablation of HDAC3 (REF. 123 ). Although both REV-ERBs and RORs are under the control of the circadian rhythm machinery, the effect of RORs on the activation of lipogenic genes during the circadian rhythm has not been examined. Regardless, 'staggerer' mice (Rora sg/sg ), which are natural mutant mice with a deletion of the gene encoding RORα, showed protection from hepatosteatosis and insulin resistance, demonstrating the activating role of RORα in lipogenic gene transcription 124 . Interestingly, peroxisome proliferator-activated receptor-δ (PPARδ), which is subjected to circadian fluctuations, was reported to control diurnal expression of hepatic lipogenic genes in the dark cycle. The authors proposed that a PPARδ-regulated hepatic metabolic programme increases phosphatidyl choline 18:0/18:1 production in the liver, which can then increase muscle fatty acid uptake for oxidation 114 .
It has recently been reported that brain and muscle ARNT-like 1 (BMAL1; also known as ARNTL), which is a core component of a circadian transcription complex
, is required to drive the feeding-and insulindependent activation of lipogenic genes in the liver by stabilizing RICTOR, which is an essential component of mTORC2 that can directly phosphorylate AKT at S473 (REF. 125 ). As the targets of BMAL1 include phosphatases and ubiquitin-specific proteases, BMAL1 was suggested to inhibit phosphorylation-dependent ubiquitylation and degradation of RICTOR, thereby promoting its stability. Thus, mTORC2 activity may be under the control of circadian rhythms and, as mentioned above, regulation of mTORC2 by RICTOR may in turn affect transcription of Srebp1c and other lipogenic genes.
It has also been reported that circadian clock deficiency can cause persistent activation of the inositolrequiring protein 1α (IRE1α) pathway for ER stress, resulting in aberrant activation of SREBPs and hepatic lipid metabolism 126 . The role of ER stress in lipogenesis will not be addressed in detail in this Review, as it has been discussed in great detail previously 127 Lipogenesis and insulin resistance Dysregulation of lipid metabolism often leads to adverse consequences, such as obesity, excess hepatic TAG accumulation -that is, hepatosteatosis -and insulin resistance. The relationships between lipogenesis and hepatosteatosis and insulin resistance, however, are complex and need better understanding at the molecular level. Hepatosteatosis can result from excessive lipogenesis due to multiple causes through insulin signalling. Various mouse models in which a component of the insulin-signalling pathway has been ablated (specifically, a liver-specific insulin receptor knockout, the liver-specific knockout of the genes encoding two p85 subunits of PI3K, the ablation of the p110α subunit of PI3K and the liver-specific knockout of Akt2) all exhibited hypolipidaemi a with reduced hepatic lipogenic gene expression. In liver-specific deletion of Pten, which is a negative regulator of insulin signalling that acts upstream of AKT, development of fatty liver and a marked increase in FAS expression are observed. Under over-nutrition conditions, PTEN-deficient mice also exhibit increased hepatic lipogenesis, as well as the development of hepatosteatosis and hypertriglyceridaemia. Furthermore, owing to the reduced suppression of gluconeogenesis resulting from impaired insulin signalling, these mice also exhibit hyperglycaemia and insulin resistance. These phenotypes demonstrate the contribution of the insulin pathway to lipogenesis and the developmen t of hepatosteatosis.
In insulin-resistant states of obesity and type 2 diabetes, hepatic lipid production is increased -paradoxically -in concert with increased hepatic glucose production. Resistance to the specific effects of insulin on the suppression of hepatic glucose production, but not lipogenesis, is referred to as selective insulin resistance. How does lipogenesis persist in insulin resistance? It has been proposed that mTORC1, which lies downstream of AKT, mediates Srebp1c induction despite the impaired signalling during insulin-resistant conditions. As mTORC1 can function independently of AKT, it does not phosphorylate and inhibit forkhead box protein O1 (FOXO1; the crucial transcription factor for gluconeogenic gene activation) as AKT normally does, and thus it promotes lipogenic gene transcription while gluconeogenic gene transcription is still active 49 . Inhibition of mTORC1 blocked i nsulininduced upregulation of Srebp1c and other lipogenic genes, independently of known mTORC1 downstream target S6K. However, mTORC1 inhibition did not affect insulin-mediated suppression of gluconeogenic genes. It is also possible that lipogenic genes are activated in insulin resistance by insulin-independent mechanisms. In this regard, the mTOR pathway is regulated by nutritional conditions. For example, mTORC signalling can be suppressed through RAPTOR upon amino acid or energy deprivation in a TSC1-TSC2-independent manner 128 . In addition, mTOR can also be inactivated by AMPKmediated phosphorylation of RAPTOR or TSC1-TSC2 (REF. 129 ). Thus, the mTOR pathway provides a potential mechanism for persistent hepatic lipogenesis even in insulin resistance.
High glucose levels in insulin resistance may also activate ChREBP for robust induction of not only glycolytic, but also lipogenic, genes. Expression levels of ChREBP are positively correlated with hepatosteatosis, and adenoviral overexpression of ChREBP in mouse liver increases hepatic TAG levels. Therefore, activation of lipogenic genes by ChREBP even when insulin signalling is blunted may partly explain sustained lipogenesis during insulin resistance. Paradoxically, ChREBP expression levels are negatively correlated with insulin resistance in humans 90 . Furthermore, HFD-induced insulin resistance is blunted by ChREBP overexpression, because ChREBP decreases the expression of gluconeogenic genes and reduces hepatic glycogen storage. Therefore, Chrebpknockout mice that were fed a high-carbohydrate diet displayed mitigated hepatosteatosis but developed severe insulin resistance 85 . It has recently been reported that the liver-specific ablation of three FOXOs prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production 130 . Conversely, overexpression of FOXO1 increased fasting glucose and reduced triglyceride levels, with impaired glucose tolerance 131 . Overall, selective insulin resistance may be the result of nutrient fluxes to the liver from the diet, from hepatic metabolism or from extra-hepatic tissues 130, 132 .
Perspectives
Hepatic lipogenesis is regulated in a complex manner in response to hormones and nutrients. Lipogenic enzymes, as well as transcription factors for lipogenic genes (such as USFs, SREBP1C, LXRs and ChREBP), are coordinately activated upon insulin and glucose signalling involving multiple downstream molecules, which include various kinases and phosphatases. These transcription factors are post-translationally modified in response to insulin and glucose, resulting in the activation of lipogenic gene transcription. Over-nutrition or dysregulation of carbohydrate and lipid metabolism can result in the accumulation of excess TAG in the liver (that is, hepatosteatosis). Although crucial transcription factors for hepatic lipogenesis have been identified and studied, more questions remain to be answered to explain the molecular details of the transcriptional regulation of lipogenesis. First, how do multiple transcription factors work together to activate lipogenic genes in a concerted manner? Second, what enzymes and post-translational events are involved in histone modification and chromatin remodelling in response to insulin and glucose? Third, are other modes of epigenetic regulation, such as DNA modification, involved in the regulation of lipogenic gene transcription? The work discussed here shows that various transcription factors and co-regulators, and the signalling pathways involved in lipogenesis, may provide future therapeutic targets for selective suppression of lipo genesis to combat insulin resistance and fatty liver disease.
